Naveen Pemmaraju, MD, provides an overview of the three classes of myeloproliferative neoplasms and the signaling pathways that drive therapeutic investigation in the field.
The Evolving Treatment Landscape for Myelofibrosis
Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.
An expert gives an overview of myelofibrosis and its different types and describes the common challenges of diagnosing patients.
Naveen Pemmaraju, MD, reviews the currently approved systemic treatment options for myelofibrosis and explains how he decides between treatment regimens.
Dr Pemmaraju explains the rationale for ruxolitinib combination therapies in myeloproliferative neoplasm treatment.
A key opinion leader details the single-agent therapies currently being investigated for the treatment of myeloproliferative neoplasms.
Naveen Pemmaraju, MD, shares the critical unmet needs in the myeloproliferative neoplasm treatment landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5